Program
TVAX-008
A development code.
Its studies are mostly in Hepatitis B, Chronic, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grand Theravac Life Sciences (Nanjing) | 33 open or running | phase 2since Sep 11, 2025 | Sep 11, 2025 | none ahead |
| Ausper Biopharma | 11 open or running | phase 2since Oct 9, 2026 | Oct 9, 2026 | Sep 22, 2028phase 2 · NCT07876856 |
| Grand Theravac Life Sciences (Hangzhou) | 11 open or running | phase 2since Oct 13, 2026 | Oct 13, 2026 | Sep 22, 2028phase 2 · NCT07897448 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 11, 2025First studies: 2 phase 2 studiesNew to Grand Theravac Life Sciences (Nanjing)Grand Theravac Life Sciences (Nanjing) · NCT07179653, NCT07190742
- Sep 24, 2025Early phase 1 study in Hepatitis B, ChronicGrand Theravac Life Sciences (Nanjing) · NCT07204236 · 20 enrolled · China
- Oct 9, 2026Ausper Biopharma's first study: phase 2 study in Hepatitis B, ChronicNew to Ausper BiopharmaAusper Biopharma · NCT07876856 · 105 planned
- Oct 13, 2026Grand Theravac Life Sciences (Hangzhou)'s first study: phase 2 study in Hepatitis B, ChronicNew to Grand Theravac Life Sciences (Hangzhou)Grand Theravac Life Sciences (Hangzhou) · NCT07897448 · 105 planned
Ahead
- Sep 22, 2028Primary completion: phase 2 study in Hepatitis B, ChronicGrand Theravac Life Sciences (Hangzhou) · NCT07897448
- Sep 22, 2028Primary completion: phase 2 study in Hepatitis B, ChronicAusper Biopharma · NCT07876856
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07897448Hepatitis B, Chronic | 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) | Sep 22, 2028 | 105 |
| NCT07876856Hepatitis B, Chronic | 2 | Not yet recruiting | Ausper Biopharma | Sep 22, 2028 | 105 |
| NCT07204236Hepatitis B, Chronic · China | Early 1 | Active, not recruiting | Grand Theravac Life Sciences (Nanjing) | Mar 1, 2025 | 20 |
| NCT07190742Hepatitis B, Chronic · China | 2 | Active, not recruiting | Grand Theravac Life Sciences (Nanjing) | Oct 17, 2024 | 80 |
| NCT07179653HBV Infection · China | 2 | Active, not recruiting | Grand Theravac Life Sciences (Nanjing) | Dec 2025 | 48 |
How it is read
Names in the registry
- “TVAX-008”, 5 entries
Codes read as this program: TVAX008.
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.